Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Free Cash Flow (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Free Cash Flow for 3 consecutive years, with -$13.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 44.66% to -$13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.2 million through Dec 2025, down 9.51% year-over-year, with the annual reading at -$49.2 million for FY2025, 9.51% down from the prior year.
  • Free Cash Flow hit -$13.3 million in Q4 2025 for Compass Therapeutics, down from -$10.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.9 million in Q3 2023 to a low of -$13.9 million in Q1 2024.
  • Historically, Free Cash Flow has averaged -$11.2 million across 3 years, with a median of -$11.5 million in 2024.
  • Biggest YoY gain for Free Cash Flow was 25.89% in 2024; the steepest drop was 87.04% in 2024.
  • Year by year, Free Cash Flow stood at -$12.4 million in 2023, then increased by 25.89% to -$9.2 million in 2024, then crashed by 44.66% to -$13.3 million in 2025.
  • Business Quant data shows Free Cash Flow for CMPX at -$13.3 million in Q4 2025, -$10.9 million in Q3 2025, and -$11.8 million in Q2 2025.